OPEN

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines

Jia Wei1,2,22, Koen B. Pouwels1,4,22, Nicole Stoesser1,3,5,6, Philippa C. Matthews1,6, Ian Diamond7, Ruth Studley7, Emma Rouke7, Duncan Cook7, John I. Bell6, John N. Newton9, Jeremy Farrar10, Alison Howarth1,6, Brian D. Marsden1,7, Sarah Hoosdally1, E. Yvonne Jones1, David I. Stuart1, Derrick W. Crook1,3,5,6, Tim E. A. Peto1,3,5,6, A. Sarah Walker1,2,3,12, David W. Eyre1,3,5,6, the COVID-19 Infection Survey team*

Antibody responses are an important part of immunity after Coronavirus Disease 2019 (COVID-19) vaccination. However, antibody trajectories and the associated duration of protection after a second vaccine dose remain unclear. In this study, we investigated anti-spike IgG antibody responses and correlates of protection after second doses of ChAdOx1 or BNT162b2 vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United Kingdom general population. In 222,493 individuals, we found significant boosting of anti-spike IgG by the second doses of both vaccines in all ages and using different dosing intervals, including the 3-week interval for BNT162b2. After second vaccination, BNT162b2 generated higher peak levels than ChAdOx1. Older individuals and males had lower peak levels with BNT162b2 but not ChAdOx1, whereas declines were similar across ages and sexes with ChAdOx1 or BNT162b2. Prior infection significantly increased antibody peak level and half-life with both vaccines. Anti-spike IgG levels were associated with protection from infection after vaccination and, to an even greater degree, after prior infection. At least 67% protection against infection was estimated to last for 2–3 months after two ChAdOx1 doses, for 5–8 months after two BNT162b2 doses in those without prior infection and for 1–2 years for those unvaccinated after natural infection. A third booster dose might be needed, prioritized to ChAdOx1 recipients and those more clinically vulnerable.

The Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1 nCoV-19 (hereafter ChAdOx1) SARS-CoV-2 vaccines have been widely used in the United Kingdom (UK) and worldwide. In the UK, vaccines were initially prioritized to older adults, frontline health and social care workers, and clinically vulnerable individuals, and then offered to other adults in decreasing age order. Up to 4 October 2021, 85% and 78% of the population (aged ≥12 years) have received one and two doses, respectively.

With widespread Alpha variant transmission, in January 2021 the UK government extended the dosing interval from 3–4 weeks to 12 weeks for all vaccines to maximize first dose coverage, based on preliminary data showing high short-term efficacy from single BNT162b2 (90%) and ChAdOx1 (70%) doses. This approach raises several questions. Although the ChAdOx1 trial found higher vaccine efficacy with dosing intervals of at least 6 weeks, BNT162b2 generated higher peak levels than ChAdOx1. Older individuals and males had lower peak levels with BNT162b2 but not ChAdOx1, whereas declines were similar across ages and sexes with ChAdOx1 or BNT162b2. Prior infection significantly increased antibody peak level and half-life with both vaccines. Anti-spike IgG levels were associated with protection from infection after vaccination and, to an even greater degree, after prior infection. At least 67% protection against infection was estimated to last for 2–3 months after two ChAdOx1 doses, for 5–8 months after two BNT162b2 doses in those without prior infection and for 1–2 years for those unvaccinated after natural infection. A third booster dose might be needed, prioritized to ChAdOx1 recipients and those more clinically vulnerable.

1Nuffield Department of Medicine, University of Oxford, Oxford, UK. 2Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK. 3The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK. 4Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK. 5The National Institute for Health Research Biomedical Research Centre, University of Oxford, Oxford, UK. 6Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK. 7Office for National Statistics, Newport, UK. 8Office of the Regius Professor of Medicine, University of Oxford, Oxford, UK. 9Health Improvement Directorate, Public Health England, London, UK. 10Wellcome Trust, London, UK. 11Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. 12MRC Clinical Trials Unit at UCL, University College London, London, UK. *These authors contributed equally: Jia Wei, Koen B. Pouwels. *A list of authors and their affiliations appears at the end of the paper. E-mail: david.eyre@bdi.ox.ac.uk
households with longitudinal follow-up, to investigate longer-term anti-trimeric spike IgG antibody responses after second ChAdOx1 or BNT162b2 vaccinations, and we quantified the effect of dosing interval, age and prior infection status on antibody peak levels and declines. We estimated the association between anti-spike IgG levels and protection against SARS-CoV-2 infection and combined these findings with estimated antibody trajectories to predict the duration of protection after second vaccination and natural infection.

Results

From 8 December 2020 to 4 October 2021, 222,493 participants received two ChAdOx1 or two BNT162b2 vaccinations and had at least one antibody measurement from 91 days before the first vaccination onward. The median (interquartile range (IQR)) age was 57 (43–68) years; 120,866 (54.3%) were female; 209,898 (94.3%) reported white ethnicity; 7,071 (3.2%) reported working in patient-facing healthcare; and 62,814 (28.2%) reported having a long-term health condition. In total, 121,322 (54.5%) and 79,693 (35.8%) participants without evidence of prior infection (Methods) received two doses of ChAdOx1 or BNT162b2, as did 12,066 (5.4%) and 9,412 (4.2%) participants with evidence of prior infection, respectively. These four cohorts contributed 723,844 anti-spike IgG measurements (Extended Data Fig. 1). The median (IQR) [range] dosing interval was 76 (68–78) [17–237] and 76 (66–78) [17–225] days for those receiving ChAdOx1 without or with prior infection, respectively, and 71 (58–77) [17–289] and 65 (56–76) [17–238] days, respectively, for BNT162b2 (Supplementary Table 1).

Anti-spike IgG response after first and second dose. In participants receiving two vaccinations without prior infection, generalized additive models (GAMs) adjusting only for age and dosing interval showed generally similar antibody trajectories for both vaccines but with higher antibody levels achieved with BNT162b2 versus ChAdOx1 (Extended Data Fig. 2a,c and Supplementary Table 2a; observed data shown in Supplementary Fig. 1). Anti-spike IgG levels increased after the first dose, peaked ~21 days later and then gradually declined until the second dose, after which they reached even higher peak levels ~21 days later and then gradually declined again. After the first dose, peak levels were lower in older participants, but age differences were attenuated after the second dose (Extended Data Fig. 3a,c and Supplementary Table 2b). In these minimally adjusted analyses (adjusted for age and dosing interval), there was no evidence of differences in antibody levels and declines after the second dose across 8–12-week dosing intervals for both ChAdOx1 and BNT162b2 vaccines. However, the antibody trajectories were different for the 3-week BNT162b2 dosing interval, where antibody levels gradually increased from the start of the first dose until around 42 days after the second dose, after which antibody levels were generally similar to those with 8–12-week dosing intervals, although slightly lower in 80-year-old participants (Extended Data Fig. 2c).

In participants with evidence of prior infection, antibody levels started from levels above 23 binding antibody units (BAU) per mliter (the positivity threshold; Methods) and gradually increased over time (up to 119 days after second vaccination; Methods). The estimated mean peak level was 959 BAU ml\(^{-1}\) (95% credible interval (CrI), 832–1,084) after the first dose, but for BNT162b2, two vaccinations without prior infection led to higher antibody levels than previously infected participants having only one dose, especially for 80-year-old participants (Fig. 1; trajectories for other dosing intervals in Extended Data Fig. 4).

Determinants of anti-spike IgG levels and half-life after the second dose. ChAdOx1. Of the 133,388 participants (with or without prior infection) who received two ChAdOx1 doses, 100,639 participants contributed 191,137 antibody measurements at least 21 days after the second dose, median (IQR) [range] 2 (1–2) [1–5] measurements per participant (Supplementary Table 3). Antibody measurements were taken at a median (IQR) [range] 61 (41–83) [21–119] days after second vaccination (Supplementary Table 3 and Supplementary Fig. 3). Assuming that antibody levels declined exponentially, using Bayesian linear mixed models we estimated a mean peak anti-spike IgG level of 184 BAU ml\(^{-1}\) (95% credible interval (Crl), 183–185) and a mean half-life of 79 days (78–80) (Extended Data Fig. 5) versus 113 BAU ml\(^{-1}\) (106–117) and 184 days (163–210), respectively, after natural infection before vaccination\(^{-1}\). There was no evidence that rates of antibody decline flattened over time (up to 119 days after second vaccination; Methods). In a multivariable model, all factors considered (age, sex, ethnicity, reporting a long-term health condition, healthcare work, deprivation, dosing interval and prior infection status) were independently associated with anti-spike IgG peak levels 21 days after the second dose, but most effects were small (Fig. 2 and Supplementary Table 4). The largest effects were associated with prior infection, peak 219 BAU ml\(^{-1}\) higher (210–227), and ethnicity, peak 41 BAU ml\(^{-1}\) (36–47) higher in those reporting non-white ethnicity. Peak levels were slightly lower in males, in those reporting a long-term health condition, in those not working in healthcare and in those with shorter dosing intervals, younger age and less deprivation (higher deprivation percentile). Prior infection extended the half-life by 13 days (95% Crl, 9–17). There were very small reductions in half-life at older ages, in non-white ethnicity and in having a long-term health condition. There was no evidence of associations between half-life and sex, being a healthcare worker and dosing interval in participants who received ChAdOx1.

BNT162b2. In 89,105 participants (with or without prior infection) who received two BNT162b2 doses, 55,053 participants contributed 120,728 antibody measurements at least 21 days after the second dose (242 days for those with 3-week dosing interval; Methods and Extended Data Fig. 2), median (IQR) [range] 2 (1–3) [1–6] per participant (Supplementary Table 3). Antibody measurements were taken at a median (IQR) [range] 79 (51–106) [21–149] days after the second vaccination (Supplementary Table 3 and Supplementary Fig. 3). The estimated mean peak level was 959 BAU ml\(^{-1}\) (95% Crl, 944–974), and the mean half-life was 51 days (50–52) (Extended Data Fig. 5). There was, again, no evidence of antibody decline flattening on the log-scale (up to 149 days after the second vaccination; Methods). Factors had greater effects on peak levels for BNT162b2 than ChAdOx1 (Fig. 2 and Supplementary Table 4). Peak levels were lower at older ages (76 BAU ml\(^{-1}\) lower per 10-years older, 95% Crl, 68–84), in males (140 BAU ml\(^{-1}\) lower, 117–164) and in those reporting a long-term health condition (79 BAU ml\(^{-1}\) lower, 55–104) and were higher in those reporting non-white ethnicity (141 BAU ml\(^{-1}\) higher, 78–208), in those working in healthcare (287 BAU ml\(^{-1}\) higher, 221–358) and in those who were less deprived (5 BAU ml\(^{-1}\) higher per ten percentiles higher, 1–10). However, these factors had little or no effect on half-life. Within dosing intervals between 8 and 12 weeks, longer dosing intervals were associated with higher peak levels (12 BAU ml\(^{-1}\) higher per week longer, 1–23) but had no effect on half-life. Compared to an 8-week extended schedule, a 3-week dosing interval was associated with a lower peak level 42 days after...
the second dose but a slightly longer half-life (6 days longer, 2–10), leading to similar antibody levels at 149 days across different dosing groups. Similarly to ChAdOx1, prior infection was associated with a much higher peak level (312 BAU ml\(^{-1}\)) and a longer half-life (11 days longer, 8–15).

Comparing the effects of factors between the two vaccines, and with our previous findings on natural infection\(^\text{16}\) (Fig. 3), effects of some factors were relatively consistent among ChAdOx1, BNT162b2 and/or natural infection, albeit with differing effect sizes (for example, sex, ethnicity, long-term health condition, working in healthcare, dosing interval on peak and prior infection on peak) or associated with only one vaccine (for example, ethnicity and working in healthcare on half-life). In general, effects on peak levels were greater for BNT162b2 than for ChAdOx1; and, other than prior infection, effects on half-life were limited for both vaccines.

**Correlates of protection.** To interpret anti-spike IgG levels over time, we investigated whether recent antibody levels are correlates of protection from infection after prior infection or vaccination in the general population. We used data from 17 May 2021 to 4 October 2021—that is, while the Delta variant accounted for nearly all cases\(^7\)—and fitted logistic GAMs for detected new infections, investigating the effect of the most recent antibody measurement obtained 21–59 days earlier on polymerase chain reaction (PCR) test results at each study visit (distribution of visits relative to first vaccination is shown in Supplementary Fig. 4 and Supplementary Table 5). Three groups were investigated: (1) unvaccinated participants with or without evidence of prior infection (6,833 participants, 12,560 visits); (2) participants vaccinated with ChAdOx1 at least 21 days previously (83,924 participants, 221,380 visits, 36–273 days after the first vaccination); and (3) participants vaccinated with BNT162b2 at least 21 days previously (49,820 participants, 124,822 visits, 35–298 days after the first vaccination). Participants tested PCR-positive at 202 (1.6%), 1,327 (0.6%) and 591 (0.5%) visits, respectively. Vaccinated participants with evidence of prior infection were excluded, as there were insufficient data to model these groups separately, and associations might differ. Adjustment was made for confounders, including age, geography and calendar time (Methods).

Compared to unvaccinated individuals with a most recent anti-spike IgG measurement of 1 BAU ml\(^{-1}\), protection against infection increased steeply as antibody levels rose in unvaccinated participants, consistent with protection from prior infection, with 50% protection at 20 BAU ml\(^{-1}\) (below the 23 BAU ml\(^{-1}\) positivity threshold) and 67% protection at 33 BAU ml\(^{-1}\). Higher antibody levels were needed to achieve the same level of protection after...
vaccination, with no evidence of differences in protection between ChAdOx1 and BNT162b2 at any given antibody level (Fig. 4a).

For example, considering antibody levels where two-thirds (67%) of individuals were protected against infection, participants vaccinated with ChAdOx1 or BNT162b2 required estimated levels of 107 BAU ml\(^{-1}\) and 94 BAU ml\(^{-1}\) (100 BAU ml\(^{-1}\) in models pooling both vaccines), respectively. However, as described above, antibody levels rose to higher levels after BNT162b2 than after ChAdOx1, explaining higher vaccine effectiveness after BNT162b2 versus after ChAdOx1 (ref. 18), with natural infection resulting in the lowest antibody levels but the greatest protection at a given antibody level (Fig. 4d–f). Protection against infection with moderate to high viral loads (cycle threshold (CT) values < 30) (Fig. 4b) and symptomatic infection (Fig. 4c) was similar. Findings were also similar when considering the maximum prior antibody measurement (which had a worse model fit), in part because of the limited time for antibody waning to occur between maximum and most recent antibody measurements (Extended Data Fig. 6).

**Duration of antibody response and association with protection.** Models of correlates of protection allowed post-vaccination antibody levels corresponding to 67% protection from Delta variant infection to be estimated (data were insufficient to estimate lower protection percentages for BNT162b2). The estimated mean time from second vaccination to antibody measurements reaching levels associated with 67% protection was 55–86 days for ChAdOx1-vaccinated participants without prior infection, with limited variation across age, sex, dosing interval or long-term health conditions (Fig. 5a). For BNT162b2, the estimated mean durations were 161–227 days and were longer at younger ages, in females and in those without long-term health conditions but were similar across different dosing intervals (Fig. 5b). For unvaccinated participants infected previously, using a model of antibody declines after natural infection\(^{15}\), the duration from diagnosis to the level associated with 67% protection was estimated to be 1–2 years (Fig. 5c).

Older people had a longer duration of protection after natural infection, but these results were conditional on seroconverting, and older individuals had lower seroconversion rates (Fig. 5d). Although data were insufficient to estimate antibody levels correlated with protection for vaccinated participants with prior infection, conservatively assuming that the threshold levels were similar to those vaccinated without prior infection, and given that their half-lives were longer, the duration of protection could last for more than 1 year. Times for antibody levels to fall to the threshold for positivity—that is, 23 BAU ml\(^{-1}\)—were longer but followed the same patterns (Extended Data Fig. 7).

We estimated the proportion of participants with 67% protection at 90, 180, 270 and 360 days from the second dose or...
natural infection based on individual-level predictions, conditional on seroconverting. At 180 days, 10% of ChAdOx1 participants without prior infection remained above the level associated with 67% protection, with little variation across different factors. For BNT162b2, the proportion varied between 40% and 80% for those without prior infection and was higher in younger ages, in females and in those without long-term health conditions. Over 90% of unvaccinated participants with natural infection were above the level required for 67% protection 180 days after diagnosis. At 270 days, almost everyone receiving ChAdOx1 or BNT162b2 fell below the level of 67% protection, whereas over 80% of unvaccinated participants were still above this threshold level (Fig. 6).

Emerging viral variants might need higher antibody levels for the same level of neutralizing activity\textsuperscript{19}. In a sensitivity analysis assuming two-fold to eight-fold increases above the threshold associated with 67% protection against the Delta variant, protection from two vaccine doses was short-lived. For example, in a 40-year-old female without any long-term health conditions and without prior infection, if three-fold higher antibody levels were required, BNT162b2 would provide around 120 days of protection, whereas ChAdOx1 did not reach the required antibody level; furthermore, if eight-fold higher antibody levels were required, the duration of protection from BNT162b2 would be reduced to only 40 days (Extended Data Fig. 8).

**Vaccine non-responders.** We previously used latent class mixed models to identify 5.8% and 5.1% of a smaller population of participants receiving one ChAdOx1 or BNT162b2 dose, respectively, as non-responders\textsuperscript{20}. Because latent class models would not fit with larger numbers, we used a heuristic rule based on these previous observations to define non-response as all antibody measurements less than 16 BAU ml\textsuperscript{−1} (similar levels to the previous non-response class) and having at least one antibody measurement 21 days after the first or second dose. To examine robustness, we also restricted to those having at least two antibody measurements and after both doses (rather than each separately). Across different assumptions (Supplementary Table 6), we found that 5.8–7.7% and 3.5–6.0% of participants were classed as non-responders to the first ChAdOx1 or BNT162b2 dose, respectively, similar to previously. Non-responders were older, had a higher percentage of males and...
Articles

NATURE MEDICINE | VOL 28 | MAY 2022 | 1072–1082 | www.nature.com/naturemedicine

white ethnicity, were more deprived, were less likely to be working in healthcare and were more likely to have long-term health conditions (Supplementary Table 7). However, only 0.4–1.0% and 0.1–0.5% of participants were non-responders to the second ChAdOx1 or BNT162b2 dose, respectively, and 0.3–0.5% and 0.1–0.2% were non-responders to both the first and second doses of ChAdOx1 or BNT162b2, respectively.

Discussion
Based on a large random sample of the UK population, we found significant boosting of anti-spike IgG after the second doses of both ChAdOx1 and BNT162b2 vaccines in all age groups and using different dosing intervals, including the 3-week dosing interval for BNT162b2. Consistent with our previous findings, those receiving BNT162b2 had significantly higher peak anti-spike IgG responses than those receiving ChAdOx1; however, their antibody levels fell faster than after ChAdOx1. After the second vaccination, older age, male sex and long-term health conditions were all associated with substantially lower peak levels in participants who received BNT162b2 but had smaller effects on peak levels with ChAdOx1. Participants with prior infection had significantly higher peak levels for both vaccines, and their antibody levels fell faster after the second ChAdOx1 dose and for 5–8 months after BNT162b2 in those without prior infection and could last for 1–2 years in those unvaccinated but seroconverting after natural infection. Similar to our previous findings, around 6–8% and 4–6% of participants were non/low-responders who did not substantially increase their antibody levels after the first ChAdOx1 or BNT162b2 dose. However, non-response to a second ChAdOx1 or BNT162b2 dose was much smaller, less than 1%, suggesting that second doses can significantly boost an initial suboptimal response in most individuals.

Antibody trajectories after vaccination differed substantially by prior infection status. Prior infection was associated with a significantly higher peak level and a longer half-life for both ChAdOx1 and BNT162b2. This is consistent with studies in healthcare workers showing that prior SARS-CoV-2 infection leads to higher antibody levels and slower waning after the second BNT162b2 vaccination. Previous studies also reported that a single dose of BNT162b2 or Sputnik V, an adenovirus-based vaccine, elicited post-vaccination antibody levels that were similar to, or higher than, those without prior infection who received two doses. From the GAMs, we found slightly lower IgG levels after a single BNT162b2 dose in previously infected participants versus those with two BNT162b2 doses without prior infection, particularly at older ages. This suggests that a second BNT162b2 dose might still be helpful for previously infected individuals where supplies are limited.

Fig. 4 | Association between anti-spike IgG levels and protection from SARS-CoV-2 infection using the most recent antibody measurement obtained 21–59 days before the current visit. a, Protection against any infection. b, Protection against infection with a moderate to high viral load (CT value < 30). c, Protection against infection with self-reported symptoms. The 95% CIs are calculated by prediction ± 1.96 x standard error of the prediction. Three groups are investigated: unvaccinated participants with or without evidence of prior infection, participants vaccinated with ChAdOx1 without evidence of prior infection and participants vaccinated with BNT162b2 without evidence of prior infection. Dots represent the median predicted individual peak levels from the Bayesian linear mixed models: 1,026 BAU ml⁻¹ for BNT162b2 (plotted at the upper quantification limit of 450 BAU ml⁻¹); 167 BAU ml⁻¹ for ChAdOx1; and 111 BAU ml⁻¹ for unvaccinated participants. Distribution of the most recent anti-spike IgG measurements for the three population groups are shown in d–f. See Supplementary Fig. 4 and Supplementary Table 5 for timing of visits relative to first vaccination.
sufficient, especially for older age groups. However, for ChAdOx1, the post-second-dose IgG levels in those without prior infection were lower than in those previously infected and vaccinated with one ChAdOx1 dose.

In an adjusted Bayesian linear mixed model, longer dosing intervals between 8 and 12 weeks resulted in higher peak antibody levels for ChAdOx1 (6 BAU ml⁻¹ per week) and BNT162b2 (12 BAU ml⁻¹ per week) but had no effect on the half-life. Consistent with this,

Fig. 5 | Posterior predicted mean days (95% CrI) from the second vaccination/infection to the threshold level associated with 67% protection. The threshold level is 107 BAU ml⁻¹ for ChAdOx1, 94 BAU ml⁻¹ for BNT162b2 and 33 BAU ml⁻¹ for unvaccinated. a, In participants without prior infection and vaccinated with ChAdOx1 (n = 92,584). b, In participants without prior infection and vaccinated with BNT162b2 (n = 51,034). c, In unvaccinated participants who had natural infection (n = 3,271). d, Predicted probability of seroconverting in unvaccinated participants who had natural infection, based on a previous model on seroconversion⁵. Estimates were separated by age, sex, dosing interval, long-term health condition (LTHC) and vaccine type for vaccinated people and by age, sex and LTHC for unvaccinated people. y axis is truncated at 800 days for visualization. For ChAdOx1, 20-year-old group is not plotted because the vast majority of those receiving ChAdOx1 were 40 years of age or older. a–c are conditional on participants having antibody response/seroconverting (see the ‘Vaccine non-responders’ section for ChAdOx1 and BNT162b2 and discussion in a previous publication⁶ for unvaccinated individuals).
Non-white ethnicity has also been previously associated with higher levels of IgG. We found that those reporting non-white ethnicity had higher IgG peak levels.

We estimated anti-spike IgG mean half-lives after second ChAdOx1 or BNT162b2 doses of 81 days and 52 days, respectively, in those without prior infection and 94 days and 63 days in those vaccinated and previously infected. The half-life of BNT162b2 was consistent with estimates from previous studies at around 50 days. Data from ChAdOx1 and mRNA-1273 vaccine trials showed higher levels of binding, and neutralizing antibodies at a limited number of time points were associated with a lower risk of infection and a longer duration of protection against new infections despite the differing design and mechanism of action of BNT162b2, an mRNA vaccine, and ChAdOx1, an adenovirus vector-based vaccine. Alternative booster vaccines might reduce vaccine-specific differences.

We estimated anti-spike IgG mean half-lives after second ChAdOx1 or BNT162b2 doses of 81 days and 52 days, respectively, in those without prior infection and 94 days and 63 days in those vaccinated and previously infected. The half-life of BNT162b2 was consistent with estimates from previous studies at around 50 days. Data from ChAdOx1 and mRNA-1273 vaccine trials showed higher levels of binding, and neutralizing antibodies at a limited number of time points were associated with a lower risk of infection and a longer duration of protection against new infections despite the differing design and mechanism of action of BNT162b2, an mRNA vaccine, and ChAdOx1, an adenovirus vector-based vaccine. Alternative booster vaccines might reduce vaccine-specific differences.

We estimated anti-spike IgG mean half-lives after second ChAdOx1 or BNT162b2 doses of 81 days and 52 days, respectively, in those without prior infection and 94 days and 63 days in those vaccinated and previously infected. The half-life of BNT162b2 was consistent with estimates from previous studies at around 50 days. Data from ChAdOx1 and mRNA-1273 vaccine trials showed higher levels of binding, and neutralizing antibodies at a limited number of time points were associated with a lower risk of infection and a longer duration of protection against new infections despite the differing design and mechanism of action of BNT162b2, an mRNA vaccine, and ChAdOx1, an adenovirus vector-based vaccine. Alternative booster vaccines might reduce vaccine-specific differences.
from the same assay are limited. We found that higher anti-spike IgG levels were associated with increased protection from infection but that the level of protection associated with a given antibody level depended on the mechanism generating the antibodies, with natural infection resulting in lower measured antibody levels but greater protection at a given antibody level compared to vaccination. We did not see evidence of vaccine-specific differences, with the greater protection from BNT162b2 versus ChAdOx1 explained by higher antibody levels rather than increased protection at a given antibody level. Using 67% protection against infection as an example threshold, protection was relatively short-lived in those not previously infected and receiving ChAdOx1. Mean levels fell below this threshold at 50–90 days after the second dose, but protection was more prolonged after two doses of BNT162b2, 160–230 days. In those without prior infection, 6 months after the second dose, only 10% of those with ChAdOx1 would maintain 67% protection, whereas 40–80% of those with BNT162b2 would still be above the threshold, indicating that a booster dose may be prioritized to those who had two doses of ChAdOx1 and would need to be individualized to optimize protection after two BNT162b2 doses. However, 9 months after the second dose of either vaccine, almost everyone without prior infection was below the threshold level associated with 67% protection. Our results are consistent with several recent studies reporting waning vaccine effectiveness 3–6 months after second BNT162b2 or ChAdOx1 vaccinations. Estimated durations of protection were much longer after natural infection, ~1–2 years for those unvaccinated. The protection in those vaccinated with prior infection could be even longer given that they have a longer half-life; however, we were not able to quantify this owing to limited data. Our estimates of correlates of protection were based on Delta variant infections and so account for the increased antibody levels needed for neutralization of this variant compared to earlier variants. However, further increases in antibody levels required for protection with other variants, such as Omicron, would substantially reduce the proportion of the population protected from infection. For example, one study found that neutralization of Omicron was eight-fold lower than Delta after two BNT162b2 vaccinations. In the case where relationships between antibody levels and levels of protection have not changed with Omicron, this would mean that antibody levels after two vaccinations would not provide effective protection against Omicron infection (Extended Data Fig. 8). Nevertheless, protection against severe infection is likely to last considerably longer and be potentially more robust. Further long-term follow-up data are essential for ongoing monitoring, as it is difficult to predict the emergence of and level of immune protection required for new variants.

Limitations of this study include the fact that, to predict vaccine effectiveness from antibody levels beyond the study follow-up, we assumed that associations between protection and antibody levels were constant over time. Even though antibody levels decrease over time, other vaccine-induced immune mechanisms, including memory responses, might theoretically provide greater protection at lower antibody levels. There might also be differences in antibody levels and classes in peripheral blood compared to potential exposure sites such as the respiratory tract. Hence, our estimated duration of protection could potentially be underestimated if other immune responses confer longer protection. However, our observations based on waning antibodies are consistent with waning of vaccine effectiveness in our cohort and other studies.

Given the scale of the study, we did not measure other immune responses, including memory-based responses and T cell or innate immune responses, which are also involved in protection against infection; they might explain the greater protection afforded by natural infection than vaccination at the same antibody level. Other study limitations include insufficient data to model two Moderna mRNA-1273 vaccine doses. We measured anti-spike IgG antibody using a single assay, with the upper limit of quantification reached by 13% and 52% of measurements after the second ChAdOx1 or BNT162b2 vaccination, respectively, potentially leading to underestimating peak levels and overestimating half-lives in those with the highest responses—for example, younger age groups. However, we used interval censored regression models to address this and capture any waning above the threshold, making it possible to estimate a higher peak level than the upper limit and a more accurate half-life. Neutralizing antibodies were not measured, but neutralization titers were strongly correlated with anti-spike IgG titers (Extended Data Fig. 9a). We also calibrated antibody levels to World Health Organization (WHO) BAU ml⁻¹ units for comparison with other studies (Extended Data Fig. 9b).

In summary, the second ChAdOx1 or BNT162b2 dose significantly boosts anti-spike IgG levels, and dosing interval has a limited effect on antibody response. Peak levels were higher after BNT162b2 than after ChAdOx1, but older individuals, males and those with long-term health conditions have lower antibody levels with BNT162b2. Protection based on the threshold level associated with 67% protection can last for 2–3 months for ChAdOx1 and for 5–8 months for BNT162b2 in those without prior infection and can be 1–2 years for those unvaccinated who seroconvert after natural infection. Those vaccinated with prior infection could be protected for more than 1 year. These results might inform vaccination strategies. A third boosting dose should be prioritized to ChAdOx1 recipients, to groups with faster antibody declines and to more clinically vulnerable individuals.

Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41591-022-01721-6.

Received: 14 November 2021; Accepted: 27 January 2022; Published online: 14 February 2022

References

1. Medicines and Healthcare products Regulatory Agency. Regulatory approval of Pfizer/BioNTech vaccine for COVID-19. https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19 (2020).
2. Medicines and Healthcare products Regulatory Agency. Oxford University/AstraZeneca COVID-19 vaccine approved. https://www.gov.uk/government/news/oxford-universityastrazeneca-covid-19-vaccine-approved (2020).
3. Department of Health and Social Care. UK COVID-19 vaccines delivery plan. https://www.gov.uk/government/publications/uk-covid-19-vaccines-delivery-plan (2021).
4. Vaccinations in United Kingdom. https://coronavirus.data.gov.uk/details/vaccinations (2021).
5. Department of Health and Social Care. Prioritising the first COVID-19 vaccine dose: JCVI statement. https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement (2021).
6. Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99–111 (2021).
7. Parry, H. et al. Extended interval BNT162b2 vaccination enhances peak antibody generation. npj Vaccines 7, 14 (2022).
8. Payne, R. P. et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell 184, 5699–5714 (2021).
9. Aniruthalingam, G. et al. Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. Nat. Commun. 12, 7217 (2021).
10. Sheikh, A., McMenamin, J., Taylor, B. & Robertson, C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 397, 2461–2462 (2021).
11. Bernal, J. L. et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N. Eng. J. Med. 385, 585–594 (2021).
12. Pouwels, K. B. et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat. Med. 27, 2127–2135 (2021).
13. Department of Health and Social Care. Most vulnerable offered second dose of COVID-19 vaccine earlier to help protect against variants. https://www.gov.uk/government/news/most-vulnerable-offered-second-dose-of-covid-19-vaccine-earlier-to-help-protect-against-variants (2021).
14. Fung, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032–2040 (2021).
15. Gilbert, P. B. et al. Immune correlates of analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43–50 (2020).
16. Wei, J. et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. Nat. Commun. 12, 6250 (2021).
17. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1025827/Technical_Briefing_25.pdf (2021).
18. Pritchard, E. et al. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat. Med. 27, 1370–1378 (2021).
19. Noori, M. et al. Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: a systematic review of in vitro studies. Rev. Med. Virol. e2277 (2021).
20. Wei, J. et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat. Microbiol. 6, 1140–1149 (2021).
21. Zhong, D. et al. Durability of antibody levels after vaccination with mRNA SARS-CoV-2 vaccine in individuals with or without prior infection. JAMA 326, 2524–2526 (2021).
22. Urbanowicz, R. A. et al. Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. Sci. Transl. Med. 13, eaay0847 (2021).
23. Buonfrate, D. et al. Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study. Clin. Microbiol. Infect. 27, 1845–1850 (2021).
24. Fraley, E. et al. The impact of prior infection and age on antibody persistence after severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine. Clin. Infect. Dis. ciaa850 (2021).
25. Vicenti, I. et al. The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects. Infection https://doi.org/10.1007/s10156-021-01680-z (2021).
26. Krammer, F. et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N. Engl. J. Med. 384, 1372–1374 (2021).
27. Ehlinger, J. E. et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat. Med. 27, 981–984 (2021).
28. Claro, F., Silva, D., Rodriguez, M., Rangel, H. R. & de Waard, J. H. Immunoglobulin G antibody response to the Sputnik V vaccine: previous SARS-CoV-2 seropositive individuals may need just one vaccine dose. Int. J. Infect. Dis. 111, 261–266 (2021).
29. Terpos, E. et al. Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine. Am. J. Hematol. 96, E257–E259 (2021).
30. Amadio, E. et al. Antibodies responses to SARS-CoV-2 in a large cohort of vaccinated subjects and seropositive patients. Vaccines (Basel) 9, 714 (2021).
31. Ward, H. et al. Vaccine uptake and SARS-CoV-2 antibody prevalence among 207,337 adults during May 2021 in England: REACT-2 study. Preprint at https://www.medrxiv.org/content/10.1101/2021.07.14.21260497v1 (2021).
32. Takahashi, T. et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 588, 315–320 (2020).
33. Bunders, M. J. & Altfeld, M. Implications of sex differences in immunity for SARS-CoV-2 pathogenesis and design of therapeutic interventions. Immunity 53, 487–495 (2020).
34. Li, C.-Y. & Sung, E.-C. A review of the healthy worker effect in occupational epidemiology. Occup. Med. (Lond.) 49, 225–229 (1999).
35. Shields, A. M. et al. Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody response. BMJ Open Respir. Res. 8, e000872 (2021).
36. Lumley, S. F. et al. The duration, dynamics, and determinants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses in individual healthcare workers. Clin. Infect. Dis. 73, e699–e709 (2021).
37. Levin, E. G. et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N. Engl. J. Med. 385, e84 (2021).
38. Sadarangani, M., Marchant, A. & Kollmann, T. R. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat. Rev. Immunol. 21, 475–484 (2021).
39. Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z. & Pierce, B. F. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat. Rev. Immunol. 21, 626–636 (2021).
40. Liu, X. et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adnoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet 398, 856–869 (2021).
41. Favresse, J. et al. Antibody titres decline 3-month post-vaccination with BNT162b2. Emerg. Microbes Infect. 10, 1495–1498 (2021).
42. van Praet, J. T. et al. Dynamics of the cellular and humoral immune response after BNT162b2 messenger ribonucleic acid Coronavirus Disease 2019 (COVID-19) vaccination in COVID-19-naive nursing home residents. J. Infect. Dis. 224, 1690–1693 (2021).
43. Maeda, K. et al. Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals. Sci. Rep. 11, 22848 (2021).
44. Tartof, S. Y. et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet 398, 1407–1416 (2021).
45. Goldberg, Y. et al. Waning immunity after the BNT162b2 vaccine in Israel. N. Engl. J. Med. 385, e85 (2021).
46. Eyre, D. W. et al. Effect of Covid-19 vaccination on transmission of Alpha and Delta variants. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2116597 (2022).
47. Bergwerk, M. et al. Covid-19 breakthrough infections in vaccinated health care workers. N. Engl. J. Med. 385, 1474–1484 (2021).
48. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1044481/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf (2021).
49. Jalkanen, P. et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat. Commun. 12, 3991 (2021).
50. Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276–280 (2021).
51. Mohamed, C. et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2119358 (2021).
52. Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205–1211 (2021).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
© The Author(s) 2022
the COVID-19 Infection Survey team

Tina Thomas⁷, Daniel Ayoubkhani⁷, Russell Black⁷, Antonio Felton⁷, Megan Crees⁷, Joel Jones⁷, Lina Lloyd⁷, Esther Sutherland⁷, Emma Pritchard¹, Karina-Doris Vihta¹, George Doherty¹, James Kavanagh¹, Kevin K. Chau¹, Stephanie B. Hatch¹, Daniel Ebner¹, Lucas Martins Ferreira¹, Thomas Christott¹, Wanwisa Dejnirattisai¹, Juthathip Mongkolsapaya¹, Sarah Cameron¹, Phoebe Tamblin-Hopper¹, Magda Wolna¹, Rachael Brown¹, Richard Cornall¹, Gavin Screaton¹, Katrina Lythgoe², David Bonsall², Tanya Golubchik², Helen Fryer², Stuart Cox¹³, Kevin Paddon¹³, Tim James¹³, Thomas House¹⁴, Julie Robotham⁹, Paul Birrell⁹, Helena Jordan¹⁵, Tim Sheppard¹⁵, Graham Athey¹⁵, Dan Moody¹⁵, Leigh Curry¹⁵, Pamela Brereton¹⁵, Ian Jarvis¹⁶, Anna Godsmark¹⁶, George Morris¹⁶, Bobby Mallick¹⁶, Phil Eeles¹⁶, Jodie Hay¹⁷, Harper VanSteenhouse¹⁷, Jessica Lee¹⁸, Sean White¹⁹, Tim Evans¹⁹, Lisa Bloemberg¹⁹, Katie Allison²⁰, Anouska Pandya²⁰, Sophie Davis²⁰, David I. Conway²¹, Margaret MacLeod²¹ and Chris Cunningham²¹

¹Oxford University Hospitals NHS Foundation Trust, Oxford, UK. ²University of Manchester, Manchester, UK. ³IQVIA, London, UK. ⁴National Biocentre, Milton Keynes, UK. ⁵Glasgow Lighthouse Laboratory, London, UK. ⁶Department of Health and Social Care, London, UK. ⁷Welsh Government, Cardiff, UK. ⁸Scottish Government, Edinburgh, UK. ⁹Public Health Scotland, Edinburgh, UK.
Methods

Population and setting. The UK’s Office for National Statistics COVID-19 Infection Survey (ISRCTN21086382) randomly selects private households on a continuous basis from address lists and previous surveys to provide a representative sample across its four countries (England, Wales, Northern Ireland and Scotland). After obtaining verbal agreement to participate, a study worker visited each household to take written informed consent from individuals 2 years of age or older. At the first visit, participants were asked for consent for optional follow-up visits every week for the next month and then monthly for 12 months or to April 2022. This consent was obtained from parents/caregivers for participants 2–15 years of age; those 10–15 years of age also provided written assent. Children younger than 2 years of age were not eligible for the study. For the current analysis, we only included participants aged 16 years or older who were eligible for vaccination for most of the study period.

Individuals were surveyed on their socio-demographic characteristics, behaviors and vaccination status. Combined nose and throat swabs were taken from all consenting household members for SARS-CoV-2 PCR testing. For a randomly 10–20% of households, individuals 16 years of age or older were invited to provide blood samples monthly for serological testing. Household members of participants who tested positive were also invited to provide blood monthly for follow-up visits. Details on the sampling design are provided elsewhere. From April 2021, additional participants were invited to provide blood samples monthly to assess vaccine responses, based on a combination of random selection and prioritization of those in the study for the longest period (independent of test results). The study protocol is available at https://www.nmdm.ox.ac.uk/covid-19-covid-19-infection-survey/protocol-and-informed-consent.html. The ethical approval was obtained from the South Central Berkshire B Research Ethics Committee (20/SC/0195).

From 8 December 2020 to 4 October 2021, 402,348 participants 16 years of age or older received two ChAdOx1 or BNT162b2 vaccinations. The median (IQR) age was 56 (41–68) years; 216,301 (53.8%) were females; and 375,880 (93.4%) reported white ethnicity. The median (IQR) deprivation percentile was 62 (38–82), and dosing interval was 74 (63–78) days. In total, 11,565 (2.9%) reported working in patient-facing healthcare, and 112,074 (27.9%) reported having a long-term health condition. Among those 402,348 participants, following the design described above with restricted blood sampling, 222,493 participants gave at least one blood sample for antibody testing from 91 days before the first vaccination onward and were included in our analyses. Participant characteristics were similar between those who did not give blood samples and those who gave blood samples for antibody measurements and were similar across participants with different numbers of antibody measurements (1–2, 3–4 and ≥5) (Supplementary Table 8).

Vaccination data. Vaccination information was obtained from participants at visits by self-report, including vaccination type, number of doses and vaccination dates. Participants from England were also linked to the National Immunisation Management Service (NIMS), which contains all individuals’ vaccination data in the English National Health Service COVID-19 vaccination program. There was good agreement between self-reported and administrative vaccination data (98% of type, 97% of date). We used vaccination data from NIMS where available for participants from England and otherwise from the survey.

Participants aged 16 years or older who received two doses of ChAdOx1 or BNT162b2 from 8 December 2020 onward with antibody measurements from 91 days before the first vaccination date up until 4 October 2021 were included in the main analysis. Only 4,219 participants received two doses of mRNA-1273 and, thus, were not included (Extended Data Fig. 1).

Laboratory testing. SARS-CoV-2 antibody levels were measured on venous or capillary blood samples using an ELISA detecting anti-trimeric spike IgG developed by the University of Oxford53,54. Normalized results are reported in ng ml−1, mAb45 monoclonal antibody equivalents. Before 26 February 2021, the assay used fluorescence detection as previously described, with a positivity threshold of 8 million units with fluorescence detection. Before 26 February 2021, the assay used fluorescence detection as previously described, with a positivity threshold of 8 million units with fluorescence detection. Given the lower and upper limits of the assay, measurements <1 BAU ml−1 (2,922 observations, 0.4%) and >450 BAU ml−1 (146,337 observations, 19.2%) were truncated at 1 BAU ml−1 and 450 BAU ml−1, respectively.

We calibrated the results of the OmniPATH assay into WHO international units (BAU ml−1) using serial dilutions of National Institute for Biological Standards and Control (NIBSC) Working Standard 21/234. The NIBSC 21/234 Working Standard was previously calibrated against the WHO International Standard for anti-SARS-CoV-2 immunoglobulin (NIBSC code 20/126), with an antibody potency of 832 ± 105 (95% confidence interval (CI) 746–929). We generated two-fold dilutions of 21/234 between 1:400 and 1:8,000 from three separate batches on three separate days. Results from a total of 63 diluted samples were merged, and a linear regression model was fitted constrained to have an intercept of zero to convert mAb45 units in ng ml−1 for samples diluted at 1:50 to BAU ml−1 (Extended Data Fig. 9b):

\[ \text{BAU/ml} = 0.559 \times (\text{mAb45 concentration in ng/ml} + 1 : 50) \]

We used ≥23 BAU ml−1 as the threshold for determining IgG positivity (corresponding to the 8 million units with fluorescence detection). Given the lower and upper limits of the assay, measurements <1 BAU ml−1 (2,922 observations, 0.4%) and >450 BAU ml−1 (146,337 observations, 19.2%) were truncated at 1 BAU ml−1 and 450 BAU ml−1, respectively.

We calibrated the results of the OmniPATH assay into WHO international units (BAU ml−1) using serial dilutions of National Institute for Biological Standards and Control (NIBSC) Working Standard 21/234. The NIBSC 21/234 Working Standard was previously calibrated against the WHO International Standard for anti-SARS-CoV-2 immunoglobulin (NIBSC code 20/126), with an antibody potency of 832 ± 105 (95% confidence interval (CI) 746–929). We generated two-fold dilutions of 21/234 between 1:400 and 1:8,000 from three separate batches on three separate days. Results from a total of 63 diluted samples were merged, and a linear regression model was fitted constrained to have an intercept of zero to convert mAb45 units in ng ml−1 for samples diluted at 1:50 to BAU ml−1 (Extended Data Fig. 9b):

\[ \text{BAU/ml} = 0.559 \times (\text{mAb45 concentration in ng/ml} + 1 : 50) \]

We used ≥23 BAU ml−1 as the threshold for determining IgG positivity (corresponding to the 8 million units with fluorescence detection). Given the lower and upper limits of the assay, measurements <1 BAU ml−1 (2,922 observations, 0.4%) and >450 BAU ml−1 (146,337 observations, 19.2%) were truncated at 1 BAU ml−1 and 450 BAU ml−1, respectively.

We calibrated the results of the OmniPATH assay into WHO international units (BAU ml−1) using serial dilutions of National Institute for Biological Standards and Control (NIBSC) Working Standard 21/234. The NIBSC 21/234 Working Standard was previously calibrated against the WHO International Standard for anti-SARS-CoV-2 immunoglobulin (NIBSC code 20/126), with an antibody potency of 832 ± 105 (95% confidence interval (CI) 746–929). We generated two-fold dilutions of 21/234 between 1:400 and 1:8,000 from three separate batches on three separate days. Results from a total of 63 diluted samples were merged, and a linear regression model was fitted constrained to have an intercept of zero to convert mAb45 units in ng ml−1 for samples diluted at 1:50 to BAU ml−1 (Extended Data Fig. 9b):

\[ \text{BAU/ml} = 0.559 \times (\text{mAb45 concentration in ng/ml} + 1 : 50) \]

We used ≥23 BAU ml−1 as the threshold for determining IgG positivity (corresponding to the 8 million units with fluorescence detection). Given the lower and upper limits of the assay, measurements <1 BAU ml−1 (2,922 observations, 0.4%) and >450 BAU ml−1 (146,337 observations, 19.2%) were truncated at 1 BAU ml−1 and 450 BAU ml−1, respectively.

We calibrated the results of the OmniPATH assay into WHO international units (BAU ml−1) using serial dilutions of National Institute for Biological Standards and Control (NIBSC) Working Standard 21/234. The NIBSC 21/234 Working Standard was previously calibrated against the WHO International Standard for anti-SARS-CoV-2 immunoglobulin (NIBSC code 20/126), with an antibody potency of 832 ± 105 (95% confidence interval (CI) 746–929). We generated two-fold dilutions of 21/234 between 1:400 and 1:8,000 from three separate batches on three separate days. Results from a total of 63 diluted samples were merged, and a linear regression model was fitted constrained to have an intercept of zero to convert mAb45 units in ng ml−1 for samples diluted at 1:50 to BAU ml−1 (Extended Data Fig. 9b):

\[ \text{BAU/ml} = 0.559 \times (\text{mAb45 concentration in ng/ml} + 1 : 50) \]
antibody declines, especially the assumption that the rate of antibody decline would flatten, we additionally fitted a model using four-knot splines for time (knots placed at 10th, 40th, 60th and 90th of observed time points) and compared the model fit with the log-linear model using the leave-one-out cross-validation information criterion (LOOCV). We found that the spline model had a higher LOOCV (indicating a worse model fit) than the log-linear model for ChAdOx1 (382,935 versus 378,640) and BNT162b2 (252,730 versus 240,472). For both vaccines, the estimated trajectories were similar, and there was no evidence of antibody decline flattening (Extended Data Fig. 10). so we used the log-linear model for the rest of the analysis.

Population-level fixed effects, individual-level random effects for intercept and slope and correlation among random effects were included in both models. The outcome was right-censored at 450 BAU ml\(^{-1}\), reflecting truncation of IgG values at the upper limit of quantification—that is, all measurements truncated to 450 BAU ml\(^{-1}\) were considered to be >450 BAU ml\(^{-1}\) in analyses. We built a multivariable model to examine the association between peak levels and antibody half-lives with continuous age (16–85 years), sex, ethnicity, report having a long-term health condition, report working in patient-facing healthcare, deprivation percentile, continuous dosing interval (7–13 weeks) and prior infection status for both vaccines. For BNT162b2, we additionally examined the effect of a 3-week dosing interval (17–28 days) by creating a binary variable and excluding antibody measurements ≤42 days after the second dose for the 3-week group (identified from the GAM as they peaked at around 42 days after the second dose).

For each Bayesian linear mixed interval censored model, weakly informative priors were used (Supplementary Table 9). Four chains were run per model with 4,000 iterations and 2,000 iterations to the burn-in. The BIC value for each was confirmed visually and by ensuring that the Gelman–Rubin statistic was less than 1.05 (Supplementary Table 10). 95% CrIs were calculated using highest posterior density intervals.

For the analysis of correlates of protection, we used data from study visits from 17 May 2021 to 4 October 2021. These visits were from 35–298 days after the first vaccination, within the time window during which real-world effectiveness has been observed to wane (Supplementary Fig. 4 and Supplementary Table 5). We grouped positive tests into episodes because PCR-positive results might be observed at multiple visits after infection. Following previous work, we defined the start of a new episode or ‘positive case’ as the date of (1) the first PCR-positive test in the study (not preceded by any study PCR-positive test); (2) a PCR-positive test after four or more consecutive negative visits; or (3) a PCR-positive test at least 120 days after the start of a previous episode with one or more negative tests immediately preceding this 10. Analyses were based on visits, dropping any visits where participants were not at risk due to a recent new positive PCR test, with new PCR-positive episodes as the outcome. We used separate logistic GAMs for three outcomes: any positive PCR episode; a positive PCR episode with a moderate to high viral load (Ct value < 30); and a positive PCR episode with self-reported symptoms. Two exposure specifications were investigated. First, we considered the effect of the most recent antibody measurement obtained 21–59 days before the current visit, excluding more recent measurements to avoid changes in antibody levels arising from recent infection that might be detected only at the routine study visit despite occurring before this. Alternatively, we considered the maximum antibody measurement obtained ≥21 days before the visit. The relationship between antibody levels and the outcome was modeled using thin plate splines. We adjusted for the following confounders in all models: geographic area (12 regions in England or in Wales, Scotland or Northern Ireland); and age in years, rural/urban home address, sex, ethnicity (white versus non-white), household size, multi-generational household, deprivation, presence of long-term health conditions, working in a care home, having a patient-facing role in health or social care, direct or indirect contact with a hospital or care home, smoking status and visit frequency. Calendar time and age were included using a tensor spline, which was allowed to vary by region/country 10. Three groups were investigated: unvaccinated participants with or without evidence of prior infection (to assess the effect of prior infection); participants vaccinated with ChAdOx1; and participants vaccinated with BNT162b2. Vaccinated participants with evidence of prior infection were excluded, as there were insufficient data to model these groups separately, and the relationship between antibody levels and protection might differ in these groups. Visits occurring in the 21 days before vaccination were excluded, as we have previously reported that infection rates change in the run-up to vaccination 16. Visits in vaccinated participants were included from ≥21 days after first vaccination. In secondary analyses, we grouped vaccinated individuals into one category.

Raw data were processed using Stata/MP 16. All analyses were performed in R version 3.6 using the following packages: tidyverse (version 1.3.0), mgcv (version 1.8–31), brms (version 2.14.0), rstanarm (version 2.22.1), splines (version 3.6.1), ggplot2 (version 0.14.3), ggrepel (version 0.3), arsenal (version 3.4.0), cowplot (version 1.1.0) and bayesplot (version 1.7.2).

Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

Data are still being collected for the COVID-19 Infection Survey. De-identified study data are available for access by accredited researchers in the Office for National Statistics Secure Research Service (SRS) for accredited research purposes under Part 5, Chapter 5, of the Digital Economy Act 2017. Individuals can apply to be an accredited researcher using the short form on https://researchaccreditationservice.ons.gov.uk/ons/ONS_registration.ofm. Accreditation requires completion of a short free course on accessing the SRS. To request access to data in the SRS, researchers must submit a research project application for accreditation in the Research Accreditation Service. Research project applications are considered by the project team and the Research Accreditation Panel established by the UK Statistics Authority at regular meetings. Project application example guidance and an exemplar of a research project application are available. A complete record of accredited researchers and their projects is published on the UK Statistics Authority website to ensure transparency of access to research data. For further information about accreditation, contact Research.Support@ons.gov.uk or visit the SRS website. Source data are provided with this paper.

Code availability

A copy of the analysis code is available at https://github.com/jacjeoxford/COVID19_second_vaccine_antibody_response.

References

53. Pouwels, K. B. et al. Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey. Lancet Public Health 6, e30–e38 (2021).
54. Ainsworth, M. et al. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect. Dis. 20, 1390–1400 (2020).
55. Supasa, P. et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell 184, 2201–2211 (2021).
56. Dejnirattisai, W. et al. The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell 184, 2183–2200 (2021).
57. Huo, J. et al. Neutralization of SARS-CoV-2 by destruction of the prefusion spike. Cell Host Microbe 28, 445–454 (2020).

Acknowledgements

We are grateful for the support of all COVID-19 Infection Survey participants. This study is funded by the Department of Health and Social Care with in-kind support from the Welsh Government and the Department of Health on behalf of the Northern Ireland Government and the Scottish Government. J.W. is supported by the University of Oxford and the China Scholarship Council. A.S.W., T.E.A.P., N.S., D.E. and K.B.P. are supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in HealthcareAssociated Infections and Antimicrobial Resistance at the University of Oxford, in partnership with the UK Health Security Agency (UKHSA) (NIHR200915). A.S.W. and T.E.A.P. are also supported by the NIHR Oxford Biomedical Research Centre. K.B.P. is also supported by the Huo Foundation Family. A.S.W. is also supported by core support from the Medical Research Council UK to the MRC Clinical Trials Unit (MC_UU_12023/22) and is an NIHR Senior Investigator. P.C.M. is funded by Wellcome (intermediate fellowship, grant ref. 110011/Z/17/Z) and holds an NIHR Oxford BRC Senior Fellowship. D.W.E. is supported by a Robertson Fellowship and an NIHR Oxford BRC Senior Fellowship. N.S. is an Oxford Martin Fellow and holds an NIHR Oxford BRC Senior Fellowship. The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, Department of Health or UKHSA.

Author contributions

This study was designed and planned by A.S.W., J.F., J.B., J.N., I.D. and K.B.P. and is being conducted by A.S.W., R.S., D.C., E.R., A.H., B.M., T.E.A.P., P.C.M., N.S., S.H., E.Y.I., D.L.S., D.W.C. and D.W.E. This specific analysis was designed by J.W., D.W.E., A.S.W. and K.B.P. J.W. and K.B.P. contributed to the statistical analysis of the survey data. J.W., D.W.E., K.B.P. and A.S.W. drafted the manuscript, and all authors contributed to interpretation of the data and results and revised the manuscript. D.W.E. and A.S.W. contributed equally. All authors approved the final version of the manuscript.

Competing interests

D.W.E. declares lecture fees from Gilead, outside the submitted work. No other author has a conflict of interest to declare.

Additional information

Extended data is available for this paper at https://doi.org/10.1038/s41591-022-01721-6.
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41591-022-01721-6.
Correspondence and requests for materials should be addressed to David W. Eyre.

Peer review information Nature Medicine thanks Gili Regev-Yochay and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Saheli Sadananda was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

Reprints and permissions information is available at www.nature.com/reprints.
Extended Data Fig. 1 | Flowchart of the study cohort. N represents the number of participants, and n represents the number of antibody measurements.
Extended Data Fig. 2 | Mean anti-spike IgG levels by time from second vaccination in 20-, 40-, 60- and 80-year-olds according to dosing interval using generalised additive models adjusted for age and dosing interval. a, Participants who received two doses of ChAdOx1 without prior infection. b, Participants who received two doses of ChAdOx1 with prior infection. c, Participants who received two doses of BNT162b2 without prior infection. d, Participants who received two doses of BNT162b2 with prior infection. Different x-axis scales reflect different durations of follow-up post-vaccination in the different cohorts. Predicted levels are plotted on a log scale. Black dotted line indicates the threshold of IgG positivity (23 BAU/mL). Black solid line indicates the second vaccination date. Line colour indicates response predicted for 3 weeks, 8–12 weeks dosing interval. The 95% CIs are calculated by prediction ± 1.96 × standard error of the prediction.
Extended Data Fig. 3 | Mean anti-spike IgG levels by time from second vaccination in 3-, 8-, 10-, and 12-week dosing interval groups according to age using generalised additive models adjusted for age and dosing interval. a, Participants who received two doses of ChAdOx1 without prior infection. b, Participants who received two doses of ChAdOx1 with prior infection. c, Participants who received two doses of BNT162b2 without prior infection. d, Participants who received two doses of BNT162b2 with prior infection. Different x axis scales reflect different durations of follow-up post-vaccination in the different cohorts. Predicted levels are plotted on a log scale. Black dotted line indicates the threshold of IgG positivity (23 BAU/mL). Red solid line indicates the first vaccination and black solid line indicates the second vaccination. Line colour indicates response predicted for age 20, 40, 60, and 80 years. The 95% CIs are calculated by prediction ± 1.96 x standard error of the prediction.
Extended Data Fig. 4 | Mean anti-spike IgG levels by time from second vaccination according to vaccine type, prior infection status, and age using generalised additive models adjusted for age and dosing interval. a, Participants with an 8-week dosing interval. b, Participants with a 12-week dosing interval. Predicted levels are plotted on a log scale. Black dotted line indicates the threshold of IgG positivity (23 BAU/mL). Red solid line indicates the first vaccination and black solid line indicates the second vaccination. Line colour indicates response predicted for ChAdOx1 and BNT162b2, with or without prior infection. The 95% CIs are calculated by prediction ± 1.96 x standard error of the prediction.
Extended Data Fig. 5 | Estimated unadjusted mean trajectory of anti-spike IgG antibody levels and individual trajectories from 21 days after the second vaccination. a, In participants who received two doses of ChAdOx1. b, In participants who received two doses of BNT162b2. Black dashed line indicates the assay threshold for IgG positivity (23 BAU/mL). For BNT162b2, interval censored regression takes account of the fact that 52% measurements were above the upper quantification limit of 450 BAU/mL, and the timing of these measurements, so the estimated peak levels were higher than 450 BAU/mL.
Extended Data Fig. 6 | Association between anti-spike IgG levels and protection from SARS-CoV-2 infection using the maximum antibody measurement obtained ≥ 21 days prior to the visit. a, protection against any infection; b, protection against infection with a moderate to high viral load (Ct value < 30); c, protection against infection with self-reported symptoms. The 95% CIs are calculated by prediction ± 1.96 × standard error of the prediction. Three groups are investigated, unvaccinated participants with or without evidence of prior infection, participants vaccinated with ChAdOx1 without evidence of prior infection, and participants vaccinated with BNT162b2 without evidence of prior infection. Dots represent the median predicted individual peak levels from the Bayesian linear mixed models: 1026 BAU/mL for BNT162b2 (plotted at the upper quantification limit of 450 BAU/mL), 167 BAU/mL for ChAdOx1, and 111 BAU/mL for unvaccinated participants. Distribution of the maximum anti-spike IgG measurements for the three population groups are shown in panel d, e, f. See Supplementary Fig. 4 and Supplementary Table 5 for timing of visits relative to second vaccination.
Extended Data Fig. 7 | See next page for caption.
Extended Data Fig. 7 | Posterior predicted mean days (95% credible interval) from the second vaccination/infection to the positivity threshold of 23 BAU/mL. a, In those without evidence of prior infection, 92,584 participants vaccinated with ChAdOx1, 51,034 participants vaccinated with BNT162b2. b, In those with evidence of prior infection, 8,055 vaccinated with ChAdOx1, 4,019 vaccinated with BNT162b2, 3,271 had natural infection and unvaccinated. Estimates were separated by age, sex, dosing interval, long-term health condition (LTHC), and vaccine type for vaccinated people, and by age, sex, and LTHC for unvaccinated people. y-axis is truncated at 1000 days (panel b) for visualisation. For ChAdOx1, 20-year-old group is not plotted because the vast majority of those receiving ChAdOx1 were ≥40 years. Estimates for the unvaccinated group in panel b are based on a previously reported biphasic model assuming the rate of antibody decline slowing over time, which may explain the longer point estimates vs ChAdOx1 or BNT162b2, however credible intervals also overlap.
Extended Data Fig. 8 | Posterior predicted days (95% credible interval) from the second vaccination to the threshold level associated with 67% protection multiplied by 2, 3, 5, 8, according to prior infection status and vaccine type. The threshold level is 107 BAU/mL for ChAdOx1 and 94 BAU/mL for BNT162b2. a, in a 40-year-old female without long-term health conditions. b, in a 60-year-old male without long-term health conditions. c, in an 80-year-old male with long-term health conditions. Estimates are based on 100,639 participants vaccinated with ChAdOx1 and 55,053 participants vaccinated with BNT162b2. All three panels were plotted at an 8-week dosing interval. LTHC: long-term health condition. Multipliers reflect the fact that higher antibody level may be required for protection against variants of concern.
Extended Data Fig. 9 | Correlation plots of anti-spike IgG levels. **a**, Correlation between anti-spike IgG levels (BAU/mL) and neutralisation titres in 37 samples. Samples were obtained from the National Institute for Biological Standards and Control (NIBSC, Potters Bar, UK) Anti-SARS-CoV-2 Verification Panel for Serology Assays (NIBSC code: 20/B770). **b**, Correlation between anti-spike IgG levels in mAb45 units (ng/ml) and WHO international units (BAU/mL) in 63 dilution replicates.
Extended Data Fig. 10 | Comparison of linear exponential model with spline-based model in examining non-linearity of antibody decline. a, Plotted in log10 scale. b, Plotted in original scale. The estimated trajectory from the spline model (with 4 knots placed at 10th, 40th, 60th, and 90th of observed time points) is similar with the linear exponential model for both ChAdOx1 and BNT162b2, indicating that there was no evidence of antibody decline flattening. Linear models provided better fit. Black dotted line shows the positivity threshold of 23 BAU/mL. Red dotted line shows the upper quantification limit of 450 BAU/mL.
Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
  
  Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g., means) or other basic estimates (e.g., regression coefficient) and variation (e.g., standard deviation) or associated estimates of uncertainty (e.g., confidence intervals)
- For null hypothesis testing, the test statistic (e.g., F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted
  
  Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g., Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

The UK’s Office for National Statistics (ONS) COVID-19 Infection Survey (CIS) randomly selects private households on a continuous basis from address lists and previous surveys. Individuals were surveyed on their socio-demographic characteristics, behaviours, and vaccination status. Combined nose and throat swabs were taken from all consenting household members for SARS-CoV-2 PCR testing. For a random 10-20% of households, individuals ≥16 years were invited to provide blood samples monthly for serological testing. Household members of participants who tested positive were also invited to provide blood monthly for follow-up visits.

De-identified study data were accessed through the Office for National Statistics (ONS) Secure Research Service (SRS). The data available in SRS were prepared and processed using Stata MP 16.

Data analysis

PCR outputs were analysed using UgenTec Fastfinder 3.300.3, with an assay-specific algorithm and decision mechanism that allows conversion of amplification assay raw data into test results with minimal manual intervention.

All statistical analyses were performed in R 3.6 using the following packages: tidyverse (version 1.3.0), mgcv (version 1.8-31), brms (version 2.14.0), rstanarm (version 2.21.1), splines (version 3.6.1), ggeffects (version 0.14.3), arsenal (version 3.4.0), cowplot (version 1.1.0), bayesplot (version 1.7.2). A copy of the analysis code is available at https://github.com/jaimeoxford/COVID19_second_vaccine_antibody_response.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.
Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy.

De-identified study data (including the COVID-19 Infection Survey data and vaccination data from NIMS) are available for access by accredited researchers in the ONS Secure Research Service (SRS) for accredited research purposes under part 5, chapter 5 of the Digital Economy Act 2017. Individuals can apply to be an accredited researcher using the short form on https://researchaccreditationservice.ons.gov.uk/ons/ONS_registration.ofm. Accreditation requires completion of a short free course on accessing the SRS. To request access to data in the SRS, researchers must submit a research project application for accreditation in the Research Accreditation Service (RAS). Research project applications are considered by the project team and the Research Accreditation Panel (RAP) established by the UK Statistics Authority at regular meetings. Project application example guidance and an exemplar of a research project application are available. A complete record of accredited researchers and their projects is published on the UK Statistics Authority website to ensure transparency of access to research data. For further information about accreditation, contact Research.Support@ons.gov.uk or visit the SRS website.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences  ☐ Behavioural & social sciences  ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-list.pdf

Life sciences study design

All studies must address these points even when the disclosure is negative.

**Sample size**

222,493 participants aged ≥16 years from the general population of the United Kingdom who had two doses of ChAdOx1 and BNT162b2 vaccinations between 8th December 2020 and 4th October 2021 contributed a total of 723,844 SARS-CoV-2 anti-spike IgG measurements taken from 91 days before the first vaccination onwards. All available data were used for the current study, with the timing of the analysis determined by the duration of follow up available, rather than sample size given the number of participants in the study.

**Data exclusions**

No available data were excluded from the study.

**Replication**

All measurements and analytical assays were undertaken once given the scale of the study and cost limitations with 100,000s of assays performed. Serially collected samples from the same participants included demonstrate reproducibility over time. The statistical analyses have been successfully replicated by two individuals.

**Randomization**

Recruitment randomised - we used data from the UK’s Office for National Statistics (ONS) COVID-19 Infection Survey (CIS) (ISRCTN21086382) which randomly selects private households on a continuous basis from address lists and previous surveys conducted by the ONS or the Northern Ireland Statistics and Research Agency to provide a representative sample across the four countries comprising the UK (England, Wales, Northern Ireland, Scotland). No intervention.

**Blinding**

Not done. This was an observational study with no interventions. Results were returned to participants to support their involvement, but this would not be expected to impact the study findings.

Reporting for specific materials, systems, and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

- ☒ Involved in the study
  - Antibodies
  - Eukaryotic cell lines
  - Palaeontology and archaeology
  - Animals and other organisms
  - Human research participants
  - Clinical data
  - Dual use research of concern

### Methods

- ☒ Involved in the study
  - ChiP-seq
  - Flow cytometry
  - MRI-based neuroimaging
Antibodies

Antibodies used

The calibrator (mAb45) provided as part of the Thermo Fisher OmniPATH 384 Combi SARS-CoV-2 IgG ELISA kit is a monoclonal antibody. It is available as part of the test kit. CR3022 and mAb269 were produced at the University of Oxford, details on availability can be provided by the authors on request.

We calibrated the results of the Thermo Fisher OmniPATH assay into WHO international units (binding antibody unit, BAU/ml) using serial dilutions of National Institute for Biological Standards and Control (NIBSC) Working Standard 21/234.

Validation

Details of the validation of the Thermo Fisher OmniPATH 384 Combi SARS-CoV-2 IgG ELISA kit are provided in the manufacturer’s instructions for use. The assay has also been validated in a head-to-head comparison of similar assays (https://doi.org/10.1016/S1473-3099(20)30634-4), where the sensitivity was 99.1% (95%CI 97.8–99.7) and specificity was 99.0% (98.1–99.5). The assay calibrant, mAb45, is described in https://doi.org/10.1016/j.cell.2021.02.032.

The CR3022 monoclonal antibody is described and validated in https://doi.org/10.1016/j.cell.2021.02.033. The mAb269 is described and validated in https://doi.org/10.1016/j.cell.2021.02.033.

Further validation of the antibodies used was performed by comparing serial dilution series of these antibodies on the test platform, ensuring a sigmoidal dose response that these saturated at the upper limit of detection. Reproducibility between batches and stability over time was also assessed using the same method. Comparisons of the performance of these antibodies on a commercial anti-S antibody detection platform are provided in https://doi.org/10.1016/j.cmi.2021.05.041.

Human research participants

Policy information about studies involving human research participants

Population characteristics

The median (IQR) age was 57 (43–68) years, 120,865 (54.3%) were female, and 209,898 (94.3%) reported white ethnicity. 7,071 (3.2%) reported working in patient-facing healthcare, and 62,814 (28.2%) having a long-term health condition. 121,322 (54.9%) and 79,693 (35.8%) participants without evidence of prior infection received two doses of ChAdOx1 or BNT162b2, as did 12,066 (5.4%) and 9,412 (4.2%) with evidence of prior infection, respectively.

Recruitment

The Office for National Statistics (ONS) COVID-19 Infection Survey (CIS) is a large household survey with longitudinal follow-up (ISRCTN21086382, https://www.ndm.ox.ac.uk/covid-19/covid-19-infection-survey/protocol-and-information-sheets) (details in 20). The study received ethical approval from the South Central Berkshire B Research Ethics Committee (20/SC/0195). Private households are randomly selected on a continuous basis from address lists and previous surveys to provide a representative sample across the UK. Following verbal agreement to participate, a study worker visited each selected household to take written informed consent for individuals aged 2 years and over. Parents or carers provided consent for those aged 2-15 years; those aged 10-15 years also provided written assent. To reduce the probability that invited individuals/households decide not to respond to the survey they are paid generously to participate in the survey, see https://www.ons.gov.uk/surveysinformationforhouseholdsandindividualsurveys/householdandindividualsurveys/covid19infectionsurveymc/howtotakepart. All participants who completed the enrolment visit was offered a £50 voucher, and one £25 voucher for each further visit. For the current analysis we only included individuals aged 16 years and over.

Nevertheless a certain degree of non-response is inevitable. While certain factors might drive non-response to invitations to participate, adjustment for covariates that may influence selection into the sample ensures that estimates of relative effects are not biased by factors that both influence selection into the sample and the risk of the outcome (model-based inference). Factors that were included in the models are listed below. We cannot exclude the possibility that other unmeasured factors that could influence self-selection into the survey and are not strongly associated with factors already included in the model could bias the result.

When fitting generalised additive models for antibody changes we adjust for age and dosing interval. When fitting the Bayesian linear mixed models, we adjust for age, sex, ethnicity, reported long-term health conditions, healthcare workers, deprivation percentiles, dosing interval, and prior infection status as covariates in the multivariable model. When fitting the generalised additive models for correlates of protection we adjusted for geographic area, age, rural-urban, sex, ethnicity, household size, multigenerational household, deprivation, presence of long-term health conditions, working in a care-home, having a patient-facing role in health or social care, direct or indirect contact with a hospital or care-home, smoking status, and visit frequency.

Ethics oversight

The study received ethical approval from the South Central Berkshire B Research Ethics Committee (20/SC/0195).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data

Policy information about clinical studies

All manuscripts should comply with the ICJME guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Clinical trial registration

ISRCTN21086382

Study protocol

https://www.ndm.ox.ac.uk/covid-19/covid-19-infection-survey/protocol-and-information-sheets
Data collection

We used data from the UK’s Office for National Statistics (ONS) COVID-19 Infection Survey (CIS) (ISRCTN21086382) from 8th September 2020 (3 months before 8th December) to 4th October 2021.

Outcomes

SARS-CoV-2 antibody levels were measured using an ELISA detecting anti-trimeric spike IgG developed by the University of Oxford (Thermo Fisher OmniPATH 384 Combi SARS-CoV-2 IgG ELISA).

Our primary analysis outcomes include:
1) We examined the peak levels and half-lives of anti-spike IgG after the second dose of ChAdOx1 or BNT162b2, and its relationship with age, sex, ethnicity, long-term health conditions, healthcare worker roles, deprivation percentile, dosing interval, and prior infection status, using Bayesian linear mixed models.
2) We examined the correlates of protection using generalised additive models with antibody levels and infections (PCR-positive visits) after vaccination.
3) Based on the above results we estimated the duration of protection from second vaccination to a level associated with 67% protection.

Our secondary analysis outcomes include:
1) We examined the changes of anti-spike IgG antibody levels post first and second dose using generalised additive models, separated by prior infection status, age, and dosing interval.
2) We examined the proportion of ‘non-responders’ who did not develop antibodies using different heuristic definitions.
3) We compared the estimates on duration of protection after second vaccinations with that after natural infection based on Bayesian linear mixed model results and correlates of protection.
4) We estimated the duration of protection from second vaccination to the positivity threshold based on Bayesian linear mixed model results.
5) We estimated the duration of protection assuming a higher antibody level was required against different variants based on Bayesian linear mixed model results and correlates of protection.